October 7, 2020 06:34 AM EDTUpdated 06:54 AM
Financing
Cell/Gene Tx

A2 Bio­ther­a­peu­tics nabs $71M-plus Se­ries B for se­lec­tive cell ther­a­py pipeline

Nicole DeFeudis

Editor

More than 15 years af­ter beat­ing can­cer him­self, A2 Bio­ther­a­peu­tics CEO Scott Forak­er has pulled in a $71.5 mil­lion Se­ries B round to send a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times